Atypical GNAO1 variants in severe childhood speech disorders: clinical, genetic, and molecular insights.
Yonika A Larasati, Moritz Thiel, Ainara Salazar-Villacorta and 6 others
PMID 41387899WHAT IT FOUND
Two children with severe speech disorders and intellectual disability carried rare GNAO1 mutations without epilepsy.
Laboratory tests showed these variants disrupt protein signaling in ways that respond to zinc, suggesting a potential treatment target and a reason to test GNAO1 in speech-only cases.
Key findings
01Both patients presented with severe speech disorders and intellectual disability but lacked the seizures or hyperkinetic movements typical of GNAO1 disorders.
02Biochemical analysis showed the GNAO1 variants caused severe defects in G-protein signaling, including impaired binding to partner proteins and abnormal chaperone interactions.
03The variants responded to zinc in the lab, leading the authors to propose zinc supplementation as a potential future treatment, though this has not yet been tested in patients.
STILL TO COME
How it was doneWhat they foundWhat it means for PTsWhat it means for OTsWhat it means for SLPs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
The study reports on only two patients, so the findings cannot be generalized or used to establish definitive genotype-phenotype correlations. The proposed benefit of zinc supplementation is based on laboratory tests only and has not been proven in clinical trials. Clinical data for a previously reported patient with a similar variant was outdated, making it difficult to determine if the motor progression seen in Patient 2 is typical for this subgroup.
Declared interests
The study was funded by the University of Geneva. No other conflicts of interest were declared.
The easy way to misread this
Do not recommend zinc supplementation for patients based on this paper. The zinc responsiveness was observed only in laboratory tests on mutant proteins, and the authors state that clinical validation is still pending.
Summarised by AI from the full paper, without a clinician reviewing it. Check it against the source before it changes what you do. Read it on PubMed →